<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310280</url>
  </required_header>
  <id_info>
    <org_study_id>01-17</org_study_id>
    <nct_id>NCT04310280</nct_id>
  </id_info>
  <brief_title>Effects of Local Insulin on Varicose Ulcers for Wound Healing</brief_title>
  <official_title>Effects of Local Insulin on Wound Angiogenesis and Fibroplasia in Varicose Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, split-plot, double-blind, placebo-controlled trial. The varicose ulcer is
      divided into two (side A and B). Half of the wound's surface is treated locally with insulin
      (Glargine) applied at an approx depth of 3-4 mm. Treatment with insulin is administered for 7
      days. Biopsy specimens of the two sides are obtained on days 0 and 7. A thermographic
      photograph of the wound is taken at days 0 and 7. The number of blood vessels and fibroplasia
      is evaluated as the main outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, split-plot, double-blind, placebo-controlled trial. Chronic Varicose Ulcers
      measuring more than 4 cm in any of its dimensions, and that comply with candidate criteria
      are included in the present study. A split-mouth model is used.

      The ulcer is divided into two (sides A and B). The side in which treatment is applied is
      randomized. Half of the wound's surface is treated locally with insulin (Glargine) applied at
      an approx depth of 3-4 mm. Both halves are covered with dressings and compression therapy is
      applied. Treatment with insulin is administered for 7 days. Biopsy specimens of the two sides
      are obtained on days 0 and 7. A thermographic photograph of the wound is taken at days 0 and
      7, as control of the local temperature of the wound. This is to asses the process of healing
      and to correlate with our outcome measures. The number of blood vessels will be evaluated as
      the main outcome. Fibroplasia and thermal asymmetry between wound sides will be evaluated as
      secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment Randomized split-plot design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator) Double Blind (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Final angiogenesis</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of blood vessels in a skin biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibroplasia</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of fibrous tissue in a skin biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thermal asymmetry</measure>
    <time_frame>Day 7</time_frame>
    <description>Difference between the temperature of the wound and the surrounding healthy tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemia</measure>
    <time_frame>Day 7</time_frame>
    <description>Presence of capillary blood glucose of &lt;60 mg/dl or clinical symptoms of hypoglycemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Venous Disease</condition>
  <condition>Varicose Ulcer</condition>
  <condition>Wound Healing</condition>
  <condition>Insulin</condition>
  <condition>Angiogenesis</condition>
  <arm_group>
    <arm_group_label>Topical insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The wound surface is treated locally with glargine insulin injected sub-dermal in a daily matter for 7 days. Allocation is randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The wound surface is treated with conventional wound care in a daily matter for 7 days. Allocation is randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Half of the wound surface is injected daily with topical glargine insulin</description>
    <arm_group_label>Topical insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Half of the wound surface is injected daily with topical saline solution</description>
    <arm_group_label>0.9% saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any gender

          -  Presence of varicose ulcer in lower extremities with a size greater than 25 cm2

          -  Absence of infection

        Exclusion Criteria:

          -  Presence of diabetes or glycated hemoglobin &gt;6.5%

          -  Comorbidities that affect wound healing

          -  Malnutrition

          -  Active smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Ramirez-GarciaLuna, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad Autónoma de San Luis Potosí</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mario Aurelio Martínez-Jiménez</name>
      <address>
        <city>San Luis Potosí</city>
        <state>San Luis Potosi</state>
        <zip>78220</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Martínez-Jiménez MA, Valadez-Castillo FJ, Aguilar-García J, Ramírez-GarciaLuna JL, Gaitán-Gaona FI, Pierdant-Perez M, Valdes-Rodríguez R, Sánchez-Aguilar JM. Effects of Local Use of Insulin on Wound Healing in Non-diabetic Patients. Plast Surg (Oakv). 2018 May;26(2):75-79. doi: 10.1177/2292550317740688. Epub 2017 Nov 22.</citation>
    <PMID>29845043</PMID>
  </results_reference>
  <results_reference>
    <citation>Martínez-Jiménez MA, Aguilar-García J, Valdés-Rodríguez R, Metlich-Medlich MA, Dietsch LJ, Gaitán-Gaona FI, Kolosovas-Machuca ES, González FJ, Sánchez-Aguilar JM. Local use of insulin in wounds of diabetic patients: higher temperature, fibrosis, and angiogenesis. Plast Reconstr Surg. 2013 Dec;132(6):1015e-9e. doi: 10.1097/PRS.0b013e3182a806f0.</citation>
    <PMID>24281606</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</investigator_affiliation>
    <investigator_full_name>MARIO AURELIO MARTÍNEZ-JIMÉNEZ</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Varicose Ulcer</keyword>
  <keyword>Wound Healing</keyword>
  <keyword>Insulin</keyword>
  <keyword>Angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymized data will be available upon request after the publication of results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

